Matches in SemOpenAlex for { <https://semopenalex.org/work/W2931497907> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2931497907 endingPage "252" @default.
- W2931497907 startingPage "243" @default.
- W2931497907 abstract "OBJECTIVE: To review the pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, tolerability, dosing, and administration of baloxavir marboxil (BXM), as well as its place in the treatment of influenza.<br/> DATA SOURCES: A search of PubMed and Google Scholar using the terms baloxavir and S-033188 was performed. The manufacturer's website was also reviewed to further identify relevant information.<br/> STUDY SELECTION/DATA EXTRACTION: All Englishlanguage articles from January 2008 to December 2018 appearing in these searches were reviewed for relevance to this paper. In addition, their bibliographies were reviewed to identify any articles not identified in the searches.<br/> DATA SYNTHESIS: BXM is a selective cap-dependent endonuclease inhibitor approved by the Food and Drug Administration for the treatment of acute uncomplicated influenza in adults and adolescents 12 years of age and older who weigh at least 40 kg. Clinical trials demonstrated that BXM was associated with a significantly shorter time to alleviation of influenza symptoms compared with placebo when taken within 48 hours of symptom onset. The time to alleviation of symptoms was similar with BXM and oseltamivir. The most common adverse reactions associated with BXM were diarrhea, bronchitis, nausea, nasopharyngitis, and headache. BXM is administered orally as a single-dose of 40 mg or 80 mg, depending on body weight. No dosage adjustment is needed in patients with mild-to-moderate hepatic or renal impairment.<br/> CONCLUSION: BXM has been proven safe and effective in the treatment of acute uncomplicated influenza in patients 12 years of age and older when administered within 48 hours of symptom onset." @default.
- W2931497907 created "2019-04-11" @default.
- W2931497907 creator A5001371756 @default.
- W2931497907 creator A5074140543 @default.
- W2931497907 creator A5080582090 @default.
- W2931497907 creator A5086206065 @default.
- W2931497907 date "2019-04-01" @default.
- W2931497907 modified "2023-09-24" @default.
- W2931497907 title "Baloxavir: A Novel Single-Dose Oral Antiviral for the Treatment of Influenza" @default.
- W2931497907 doi "https://doi.org/10.4140/tcp.n.2019.243" @default.
- W2931497907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30935446" @default.
- W2931497907 hasPublicationYear "2019" @default.
- W2931497907 type Work @default.
- W2931497907 sameAs 2931497907 @default.
- W2931497907 citedByCount "3" @default.
- W2931497907 countsByYear W29314979072021 @default.
- W2931497907 countsByYear W29314979072023 @default.
- W2931497907 crossrefType "journal-article" @default.
- W2931497907 hasAuthorship W2931497907A5001371756 @default.
- W2931497907 hasAuthorship W2931497907A5074140543 @default.
- W2931497907 hasAuthorship W2931497907A5080582090 @default.
- W2931497907 hasAuthorship W2931497907A5086206065 @default.
- W2931497907 hasConcept C111113717 @default.
- W2931497907 hasConcept C112705442 @default.
- W2931497907 hasConcept C126322002 @default.
- W2931497907 hasConcept C142724271 @default.
- W2931497907 hasConcept C197934379 @default.
- W2931497907 hasConcept C204787440 @default.
- W2931497907 hasConcept C27081682 @default.
- W2931497907 hasConcept C2777056448 @default.
- W2931497907 hasConcept C2777288759 @default.
- W2931497907 hasConcept C2778375690 @default.
- W2931497907 hasConcept C2779802037 @default.
- W2931497907 hasConcept C2780035454 @default.
- W2931497907 hasConcept C2780580376 @default.
- W2931497907 hasConcept C535046627 @default.
- W2931497907 hasConcept C71924100 @default.
- W2931497907 hasConcept C98274493 @default.
- W2931497907 hasConceptScore W2931497907C111113717 @default.
- W2931497907 hasConceptScore W2931497907C112705442 @default.
- W2931497907 hasConceptScore W2931497907C126322002 @default.
- W2931497907 hasConceptScore W2931497907C142724271 @default.
- W2931497907 hasConceptScore W2931497907C197934379 @default.
- W2931497907 hasConceptScore W2931497907C204787440 @default.
- W2931497907 hasConceptScore W2931497907C27081682 @default.
- W2931497907 hasConceptScore W2931497907C2777056448 @default.
- W2931497907 hasConceptScore W2931497907C2777288759 @default.
- W2931497907 hasConceptScore W2931497907C2778375690 @default.
- W2931497907 hasConceptScore W2931497907C2779802037 @default.
- W2931497907 hasConceptScore W2931497907C2780035454 @default.
- W2931497907 hasConceptScore W2931497907C2780580376 @default.
- W2931497907 hasConceptScore W2931497907C535046627 @default.
- W2931497907 hasConceptScore W2931497907C71924100 @default.
- W2931497907 hasConceptScore W2931497907C98274493 @default.
- W2931497907 hasIssue "4" @default.
- W2931497907 hasLocation W29314979071 @default.
- W2931497907 hasOpenAccess W2931497907 @default.
- W2931497907 hasPrimaryLocation W29314979071 @default.
- W2931497907 hasRelatedWork W1573667742 @default.
- W2931497907 hasRelatedWork W1978032370 @default.
- W2931497907 hasRelatedWork W1979757582 @default.
- W2931497907 hasRelatedWork W2004325424 @default.
- W2931497907 hasRelatedWork W2332367370 @default.
- W2931497907 hasRelatedWork W2400461952 @default.
- W2931497907 hasRelatedWork W2793520024 @default.
- W2931497907 hasRelatedWork W282266550 @default.
- W2931497907 hasRelatedWork W3021369409 @default.
- W2931497907 hasRelatedWork W79555446 @default.
- W2931497907 hasVolume "34" @default.
- W2931497907 isParatext "false" @default.
- W2931497907 isRetracted "false" @default.
- W2931497907 magId "2931497907" @default.
- W2931497907 workType "article" @default.